Patient characteristics
| Characteristic . | N = 30 (100%) . |
|---|---|
| Age, median (range), y | 63 (18-82) |
| Sex, male, n (%) | 19 (63) |
| ECOG PS, n (%) | |
| 0 | 9 (30) |
| 1 | 21 (70) |
| Ann Arbor stage, n (%) | |
| I-II | 6 (20) |
| III-IV | 24 (80) |
| B-NHL subtype, n (%) | |
| DLBCL | 19 (63) |
| trFL | 7 (23) |
| PMBCL | 1 (3) |
| FL | 3 (10) |
| Cell of origin (DLBCL, trFL), n (%) | |
| GCB | 14 (54) |
| Non-GCB | 12 (46) |
| Unknown | 1 (4) |
| Double hit∗ lymphoma, n (%) | 2 (7) |
| Bulky disease >10 cm, n (%) | 1 (3) |
| Prior lines of therapy, median (range) | 4 (3-8) |
| 3 previous lines, n (%) | 7 (23) |
| >3 previous lines, n (%) | 23 (77) |
| Prior lymphoma therapies, n (%) | |
| Anti-CD20 antibody | 30 (100) |
| Anthracycline | 30 (100) |
| CAR-T | 30 (100) |
| Prior ASCT | 4 (13) |
| Response to prior therapies, n (%) | |
| Refractory† to last therapy | 25 (83) |
| Relapsed after last therapy | 5 (17) |
| Refractory to any prior anti-CD20 | 27 (90) |
| Refractory to CAR-T | 24 (80) |
| Characteristic . | N = 30 (100%) . |
|---|---|
| Age, median (range), y | 63 (18-82) |
| Sex, male, n (%) | 19 (63) |
| ECOG PS, n (%) | |
| 0 | 9 (30) |
| 1 | 21 (70) |
| Ann Arbor stage, n (%) | |
| I-II | 6 (20) |
| III-IV | 24 (80) |
| B-NHL subtype, n (%) | |
| DLBCL | 19 (63) |
| trFL | 7 (23) |
| PMBCL | 1 (3) |
| FL | 3 (10) |
| Cell of origin (DLBCL, trFL), n (%) | |
| GCB | 14 (54) |
| Non-GCB | 12 (46) |
| Unknown | 1 (4) |
| Double hit∗ lymphoma, n (%) | 2 (7) |
| Bulky disease >10 cm, n (%) | 1 (3) |
| Prior lines of therapy, median (range) | 4 (3-8) |
| 3 previous lines, n (%) | 7 (23) |
| >3 previous lines, n (%) | 23 (77) |
| Prior lymphoma therapies, n (%) | |
| Anti-CD20 antibody | 30 (100) |
| Anthracycline | 30 (100) |
| CAR-T | 30 (100) |
| Prior ASCT | 4 (13) |
| Response to prior therapies, n (%) | |
| Refractory† to last therapy | 25 (83) |
| Relapsed after last therapy | 5 (17) |
| Refractory to any prior anti-CD20 | 27 (90) |
| Refractory to CAR-T | 24 (80) |
ASCT, autologous hematopoietic stem cell transplantation; B-NHL, B-cell non-Hodgkin lymphoma; CAR-T, chimeric antigen receptor–modified T cells; DLBCL, diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group Performance Status; FL, follicular lymphoma; GCB, germinal center B-cell-like subtype; PMBCL, primary mediastinal large B-cell lymphoma; trFL, large cell transformation of follicular lymphoma.
MYC and BCL2 and/or BCL6 FISH translocations.
Refractory is defined as stable or progressive disease after the indicated therapy.